TABLE 1.
General characteristics of HIV-1 SCs selected from the MACS, DCG cohort, and SFMHS
| HIV-1 SCs (n)a | Mean age (yr) | Median sero- conversion intervalb | No. of AIDS cases/ median AIDS- free time (yr) | No. of deaths/median survival | Mean HIV-1 RNA level (log10 copies/ml) in plasmac
|
||||
|---|---|---|---|---|---|---|---|---|---|
| <6 mo | 6–18 mo | 19–30 mo | 31–42 mo | 6–42 mo | |||||
| MACS | |||||||||
| Caucasians (341) | 34.4 | 6 | 163/8.4 | 129/10.1 | 4.3 (275) | 4.3 (281) | 4.3 (258) | 4.3 (219) | 4.3 (341) |
| African Americans (31) | 31.7 | 6 | 8/10.9 | 7/11.1 | 4.4 (29) | 4.4 (28) | 4.3 (22) | 4.3 (16) | 4.4 (31) |
| DCG (39) | 35.2 | 12 | 19/8.1 | 22/9.1 | 4 (7) | 4.3 (33) | 4.4 (23) | 4.1 (19) | 4.2 (39) |
| SFMHS (37) | 36.9 | 7 | 16/9.3 | 3.5 (23)* | 3.9 (24)*** | 3.6 (20)** | 3.9 (20) | 3.8 (37)**** | |
a
Total number of eligible SCs as defined by seroconversion interval and number of HIV-1 RNA measurements at any given interval (see text).
b
Seroconversion interval = difference (months) between date of last seronegative visit and date of first seropositive visit.
c
Range of time intervals from date of estimated seroconversion to median date of assay for HIV-1 RNA levels. Total numbers of measurements (subjects) are shown in parentheses. HIV RNA levels in SFMHS SCs differed from those in MACS SCs at these intervals according to pooled t tests: *, P < 0.05; **, < 0.01; ***, P < 0.001; ****, P < 0.0001.